This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Psoriasis Vulgaris
and you are
over 18
years old
Phase
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

A Phase 2 Maximal Use Systemic Exposure (MUSE) study evaluating the safety and efficacy of LEO 90100 used once daily in subjects with extensive psoriasis vulgaris.

Provided treatments

  • Drug: LEO 90100
Tris trial is registered with FDA with number: NCT01600222. The sponsor of the trial is LEO Pharma and it is looking for 37 volunteers for the current phase.
Official trial title:
A Phase 2 Maximal Use Systemic Exposure (MUSE) Study Evaluating the Safety and Efficacy of LEO 90100 Used Once Daily in Subjects With Extensive Psoriasis Vulgaris